Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
TABLE OF CONTENTS | |||||||||||||||||||||||||||||||||||||
October 2013 Volume 10 Number 10 | |||||||||||||||||||||||||||||||||||||
In this issue Research Highlights News and Views Correspondence Reviews
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
NEWS AND VIEWS | Top | ||||||||||||||||||||||||||||||||||||
Coronary artery disease: Variation in ischaemic heart disease between EU countries Fausto J. Pinto Published online: 06 August 2013 p555 | doi:10.1038/nrcardio.2013.116 Ischaemic heart disease (IHD) causes a large number of deaths in the European Union, but a new study reveals important inequalities in IHD mortality between countries. Surveillance systems might help to identify these differences and define tailored treatment strategies, so that the burden of IHD can be reduced across Europe. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Valve disease: Is early surgery beneficial in prosthetic valve endocarditis? Bernard Prendergast & James Harrison Published online: 03 September 2013 p556 | doi:10.1038/nrcardio.2013.130 Prosthetic valve endocarditis (PVE) is a devastating disease, and guidelines currently recommend early surgery in patients with PVE and associated complications. However, a study from the International Collaboration on Endocarditis suggests that, after correcting for treatment selection bias and survivor bias, early surgery might not be beneficial. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Congenital heart conditions: Patent foramen ovale closure—not all devices are equal Bernhard Meier Published online: 03 September 2013 p558 | doi:10.1038/nrcardio.2013.136 Debate surrounds the best method of treating patent foramen ovale (PFO). Randomized trials suggest that catheter-based closure of PFO is beneficial for secondary stroke prevention; however, with multiple devices available, which performs best in a head-to-head trial? A paper published in the European Heart Journal might have the answer. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
CORRESPONDENCE | Top | ||||||||||||||||||||||||||||||||||||
Targeting RV failure and cardiomyocyte injury in acute pulmonary thromboembolism Jose E. Tanus-Santos Published online: 20 August 2013 p559 | doi:10.1038/nrcardio.2013.12-c1 Full Text | PDF | |||||||||||||||||||||||||||||||||||||
REPLY | Top | ||||||||||||||||||||||||||||||||||||
Matrix metalloproteinases in right ventricular failure Marc A. Simon Published online: 20 August 2013 p559 | doi:10.1038/nrcardio.2013.12-c2 Full Text | PDF | |||||||||||||||||||||||||||||||||||||
REVIEWS | Top | ||||||||||||||||||||||||||||||||||||
Pharmacotherapies for lipid modification: beyond the statins Antonio M. Gotto, Jr & Jennifer E. Moon Published online: 20 August 2013 p560 | doi:10.1038/nrcardio.2013.117 Statins are the first-line therapy for the prevention and treatment of atherosclerotic vascular disease; however, various other lipid-lowering agents can provide additional beneficial effects when to statin therapy or alternatives for patients who are intolerant to statins. In this Review, Antonio Gotto Jr and Jennifer Moon discuss the mechanisms of action, indications, and clinical data for existing pharmacotherapies for lipid modification, as well as trials of investigational agents that are being developed for cardiovascular risk reduction. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Genetic testing for inherited cardiac disease Arthur A. M. Wilde & Elijah R. Behr Published online: 30 July 2013 p571 | doi:10.1038/nrcardio.2013.108 Cardiomyopathies and cardiac channelopathies can predispose individuals to sudden cardiac death. The genetics that underlie these phenotypes are complex and incompletely understood. In this Review, Wilde and Behr discuss the indications for genetic testing of index patients, and its use in cascade testing of family members, to guide diagnosis, management, and assessment of prognosis. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Cardiac contractility modulation therapy in advanced systolic heart failure Alexander R. Lyon, Michael A. Samara & David S. Feldman Published online: 13 August 2013 p584 | doi:10.1038/nrcardio.2013.114 Cardiac contractility modulation has positive inotropic effects in the failing heart, without increasing oxygen consumption. Here, Lyon and colleagues review the preclinical data, mode of action, and clinical evidence for the use of this therapy in patients with chronic heart failure. Long-term application of cardiac contractility modulation seems to improve exercise tolerance and quality of life, and have an acceptable safety profile. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Update on atrial fibrillation catheter ablation technologies and techniques Jane Dewire & Hugh Calkins Published online: 27 August 2013 p599 | doi:10.1038/nrcardio.2013.121 Atrial fibrillation is one of the most common heart arrhythmias. In this Review, Dewire and Calkins discuss the development and role of catheter ablation to electrically isolate the pulmonary veins in patients with paroxysmal, persistent, or longstanding persistent atrial fibrillation. They go on to highlight novel tools that improve the safety, efficacy, and precision of ablation techniques. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
|
*Journal Citation Reports, Thomson, 2012. Nature Reviews Cardiology was previously published as Nature Clinical Practice Cardiovascular Medicine. |
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
No comments:
Post a Comment